@article {Rossignol2021.04.19.21255441, author = {Jean-Fran{\c c}ois Rossignol and C. Bardin Matthew and Joshua B. Oaks and B. Gregory Bostick and Kishor N. Vora and Jessica Fulgencio and Dena Mogelnicki and Christian Br{\'e}chot and Vanguard Study Group}, title = {Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization}, elocation-id = {2021.04.19.21255441}, year = {2021}, doi = {10.1101/2021.04.19.21255441}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background There is an urgent need for treatments to prevent the progression to severe COVID-19 and hospitalization.Methods A randomized double-blind placebo-controlled clinical trial in 36 centers in the U.S. and Puerto Rico investigated the safety and effectiveness of oral nitazoxanide 600 mg twice daily for 5 days in outpatients with symptoms of mild or moderate COVID-19 enrolled within 72 hours of symptom onset. Key objectives were reduction of duration of symptoms (primary) and progression to severe illness (key secondary).Results 1,092 subjects were enrolled, and 379 with laboratory-confirmed SARS-CoV-2 infection were analyzed. Overall, times to sustained clinical recovery were similar for the two arms. Nitazoxanide treatment was associated with an 85\% reduction in the progression to severe COVID-19 (1/184, [0.5\%] vs. 7/195, [3.6\%], p=0.07) and 82\% reduction in the rate of hospitalization, emergency room visit or death (1/184 [0.5\%] vs. 6/195 [3.1\%], p=0.12). In subjects with mild illness at baseline, treatment was also associated with a 3.1-day reduction in median time to sustained clinical recovery and a 5.2-day reduction in time to return to usual health. Nitazoxanide was safe and well tolerated.Conclusions Treatment of mild or moderate COVID-19 with a five-day course of oral nitazoxanide was safe and well tolerated and was associated with an 85\% reduction in the progression to severe illness and a 3- to 5-day reduction of the duration of mild illness.Competing Interest StatementJean-Francois Rossignol is an employee of and owns equity interest in Romark, L.C. Mathew Bardin, Jessica Fulgencio and Dena Mogelnicki are employees of Romark, L.C.; Christian Brechot is a senior adviser for Romark, L.C., an adviser for the Theravectys, Shanghai Vivo Biosciences and the chairman of The Healthy Aging company.Clinical TrialNCT04486313Funding StatementThis study was funded by the Romark Institute of Medical Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IntegReview IRB 3815 S. Capital of Texas Highway Suite 320 Austin, Texas 78704All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReasonable requests from qualified researchers will be considered for data sharing. These requests should be submitted to medinfo{at}romark.com.}, URL = {https://www.medrxiv.org/content/early/2021/07/17/2021.04.19.21255441}, eprint = {https://www.medrxiv.org/content/early/2021/07/17/2021.04.19.21255441.full.pdf}, journal = {medRxiv} }